Tissue microarrays for testing basal biomarkers in familial breast cancer cases

Sao Paulo Medical Journal

Volumn 125, Issue 4, 2007, Pages 226-230

  Dufloth, Rozany Mucha ^a,b,e   Matos, Irina ^c   Schmitt, Fernando ^d   Zeferino, Luiz Carlos ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSITY OF PORTO   (Portugal)

^d University of Porto   (Portugal)

^e Universidade Estadual de Campinas ^*  (Brazil)

Author keywords

Biological markers; Breast neoplasms; Genetic markers; Immunohistochemistry; Inborn genetic diseases

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROTEIN P63;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CONTROLLED STUDY; CRITERION VARIABLE; FAMILIAL CANCER; FEMALE; GENETIC MARKER; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 36749028378     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802007000400007     Document Type: Article

References (33)

1. Deugnier MA, Teuliere J, Faraldo MM, Thiery JP, Glukhova MA. The importance of being a myoepithelial cell. Breast Cancer Res. 2002;4(6):224-30.
2. Bimbaum D. Bettucci F, Ginestier C, Tagett R. Jacquemier J, Charafe-Jauffret E. Basal and luminal breast cancers: basic or luminnous? (review). Int J Oncol. 2004; 25(2):249-58.
3. Perou CM, Sorlie T. Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52.
4. DiRenzo J, Signoretti S, Nakamura N, et al Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res. 2002; 62(1):89-98.
5. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6.
6. Sorlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underlying dinically relevant subtypes of breast cancer. gene expression analyses across three different platforms BMC Genomics 2006; 7:127.
7. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev Cancer. 2002; 2(2):101-12.
8. Callagy, G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mel Pathol. 2003; 12(1):27-34.
9. Maros I, Dufloth R, Alvarenga M, Zeferino LC, Sehmitt F. p63, cytokeratin 5, and P-eadherin: three molecular markets to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005; 447(4):688-94.
10. Bocker W, Moll R, Poremba C, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest. 2002; 82(6):737-46.
11. Boecker W, Buerger H. Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif 2003; 36(Suppl 1):73-84.
12. Reis-Filho JS, Simpson PT. Martins A. Preto A. Gartner F, Schmitt FC. Distribution, of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch, 2003, 443(2):122-32.
13. McKeon F. p63 and the epithelial stem cell: more than status quo? Genes Dev. 2004; 18(5):465-9.
14. Westfall MD, Pietenpol JA. p63: Molecular complexity in delopment and cancer. Carcinogenesis. 2004; 25(6):857-64.
15. Peralta Soler A. Knudsen KA, Salazar H, Han AC, Keshgegian AA. P-cadherin expression in breast carcinoma indicates poor survival. Cancer. l999; 86(7)A263-72.
16. Paredes J, Milanezi F, Reis-Filho JS, Leitão D, Athanazio D, Schmitt F. Abettant P-eadherin expression: is it associated with estrogen-independent growth in breast cancer? Pathol Res Pract. 2002; 198(12):795-801.
17. Han AC, Soler AP, Knudsen KA, Salazar H. Distinct cadhetin profiles in special variant carcinomas and other tumors of the breast. Hum Pathol. 1999; 30(9):1035-9.
18. Gamallo C, Moreno-Bueno G, Sarrió D, Calero F, Hardisson D, Palacios J. The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. Mod Pathol. 2001; 14(7):650-4.
19. Madhavan M, Srinivas P, Abrahaan E, et al. Cadherins as predictive markets of nodal metastasis in breast cancer, Mod Pathol. 2001; 14(5):423-7.
20. Palacios J, Honrado E, Osorio A. et al. Immunohistochemical characteristic defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res. 2003; 9(10 Pt 1):3606-14.
21. Palacios J, Honrado E, Osorio, A, Diez O, Rivas C, Berftez. J. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2004; 96(9):712-4.
22. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet. 1997; 349(9064):1505-10.
23. Ford D. Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62(3):676-89.
24. Reis-Filho JS, Milanezi F, Paredes J, et al. Novel and classic myoepithelial/stem cell markets in meraplastic carcinomas of the breast. Appl, Immunohistochem Mol Morphol. 2003; 11(1):1-8.
25. Aluman DG. Practical statistics for medical research. London: Chapman & Hall; 1991.
26. Foulkes WD. BRCA1 functions as a breast stem cell regulator. J Med Genet. 2004; 41(1):1-5.
27. Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer. 2001; 85(6):869-74.
28. Aubele MM, Cummings MC, Mattis AE, et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast canoer. Diagn Mol Pathol. 2000; 9(1):14-9
29. Farabegoli F, Champeme MH, Bieche I, et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol. 2002; 196(3):280-6.
30. Lee JS, John EM, McGuire V, et al. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev. 2006; 15(2):359-63.
31. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status, in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11(14):5175-80.
32. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germiline BRCA1 mutations and a basal epithelial phenotype in breast canncer J Natl Cancer Insr. 2003; 95(19):1482-5.
33. Tischkowitz MD, Foulkes WD. The basal phenotype of BRCA1-related breast cancer. pasa, present and future. Cell cycle. 2006; 5(9):963-7.